DBV Technologies reported $-22216179.61 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US USD -26415000 7.15M
Alnylam Pharmaceuticals ALNY:US USD -329357000 54.68M
Amarin AMRN:US USD -3883000 60.92M
Esperion Therapeutics ESPR:US USD -55117000 11.21M
Galectin Therapeutics GALT:US USD -8597000 1.02M
Halozyme Therapeutics HALO:US USD 73.71M 21.78M
Insmed INSM:US USD -130773000 35.63M
Intercept Pharmaceuticals ICPT:US USD -104087000 83.77M
Neurocrine Biosciences NBIX:US USD 97.9M 121.2M
Ptc Therapeutics PTCT:US USD -127208000 21.49M
Sarepta Therapeutics SRPT:US USD -256418000 28.32M
Ultragenyx Pharmaceutical RARE:US USD -238819000 80.96M
United Therapeutics UTHR:US USD 312.5M 161.9M
YTE INCY:US USD 178.22M 131.36M